Keywords: vernalis, loss, up, apokyn, costs, uk-based, biopharmaceutical
Vernalis' 2006 loss up 29% on Apokyn costs
Article | 19 March 2007
UK-based biopharmaceutical company Vernalis says that its net loss for the full year 2006 was L42.4 million ($82.0 million), an increase of 29.3% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
